%0 Journal Article
%T Control of prostate cancer associated with withdrawal of a supplement containing folic acid, L-methyltetrahydrofolate and vitamin B12: a case report
%A Glenn Tisman
%A April Garcia
%J Journal of Medical Case Reports
%D 2011
%I BioMed Central
%R 10.1186/1752-1947-5-413
%X Our patient is a 71-year-old Caucasian man who had been diagnosed in 1997 with prostate cancer, stage T1c, and Gleason score 3+4 = 7. His primary treatment included intermittent androgen deprivation therapy including leuprolide + bicalutamide + deutasteride, ketoconazole + hydrocortisone, nilandrone and flutamide to resistance defined as biochemical relapse of PSA. While undergoing docetaxel therapy to treat a continually increasing prostate-specific antigen level, withdrawal of 10 daily doses of a supplement containing 500 ¦Ìg of vitamin B12 as cyanocobalamin, as well as 400 ¦Ìg of folic acid as pteroylglutamic acid and 400 ¦Ìg of L-5-methyltetrahydrofolate for a combined total of 800 ¦Ìg of mixed folates, was associated with a return to a normal serum prostatic-specific antigen level.This case report illustrates the importance of the effects of supplements containing large amounts of folic acid, L-5-methyltetrahydrofolate, and cyanocobalamin on the metabolism of prostate cancer cells directly and/or B vitamin interference with docetaxel efficacy. Physicians caring for patients with prostate cancer undergoing watchful waiting, hormone therapy, and/or chemotherapy should consider the possible acceleration of tumor growth and/or metastasis and the development of drug resistance associated with supplement ingestion. We describe several pathways of metabolic and epigenetic interactions that could affect the observed changes in serum levels of prostate-specific antigen.The clinical course of our patient with hormone-refractory or hormone-resistant prostate cancer appears to have been affected by ingestion followed by withdrawal of a vitamin supplement containing a mixture of large amounts of folic acid (FA), L-methyltetrahydrofolate (L-methyl-THF, or folate) and cyanocobalamin (vitamin B12). Prior to supplement withdrawal, the patient had been treated with docetaxel for 18 weeks but had a continuous rise in serum prostatic-specific antigen (PSA) levels. Only after withdrawa
%U http://www.jmedicalcasereports.com/content/5/1/413